Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Elekta AB ( ($SE:EKTA.B) ) has provided an update.
Elekta has outlined a new strategic direction centered on growth, innovation and operational efficiency, anchored in a revamped operating model. As part of this transformation, the company will cut 450 jobs, targeting annual cost savings of more than SEK 500 million from the first quarter of fiscal 2026/27, and will take a restructuring charge of SEK 450–500 million in the second half of 2025/26. Management frames this effort as the first of four “must-win battles” under the banner “Simplify, Empower, Speed,” aimed at streamlining decision-making, strengthening customer relationships and improving execution predictability. The other strategic priorities—Focused Innovation, winning market share in the U.S., expanding in China, and reducing cost of goods sold—are intended to accelerate value creation and sharpen Elekta’s competitive position in key markets, with more detailed financial plans to be presented at a capital markets day in June.
The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK52.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.
More about Elekta AB
Elekta is a Stockholm-headquartered leader in precision radiation therapy, developing technology and solutions to improve access to advanced, cost-efficient cancer care. With around 4,500 employees and offices in more than 40 countries, the company focuses on outcome-driven innovations for radiotherapy and related oncology treatments, serving hospitals and cancer centers worldwide and listed on Nasdaq Stockholm.
Average Trading Volume: 1,352,599
Technical Sentiment Signal: Hold
Current Market Cap: SEK23.04B
Learn more about EKTA.B stock on TipRanks’ Stock Analysis page.